PEDIATRICS Vol. 78 No. 3 September 1986, pp. 541
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by JACKSON, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by JACKSON, D.

Doxapram and Potential Benzyl Alcohol Toxicity: A Moratorium on Clinical Investigation?

DAVID JACKSON MD1

1 Director, Office of Medical Research, A. H. Robins Company, Inc, 1211 Sherwood Ave, Richmond, VA 23220

In Reply.—

We read with interest and due concern the letter of Dr Jordan et al about the potential risk of benzyl alcohol toxicity in premature newborns who received infusions of Dopram Injectable (containing benzyl alcohol 0.9% as a preservative) for treatment of apnea.

In May 1982, the Food and Drug Administration issued a "Dear Doctor" letter and, in August 1982, published an article in the FDA Drug Bulletin raising concerns about the use of solutions containing benzyl alcohol or other prcservatives in treating newborns.